DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

CLOMID (clomiphene citrate),
1841–1843
Clomiphene, 1179
adverse effects and side effects of,
1843
teratogenicity of, 1843
Clomiphene citrate, 1841–1843
Clomipramine
disposition of, 409t
dose and dosage forms of, 400t
polymorphisms and response to,
160t
potencies
at human transporters for
monamine neurotransmitters,
406t
at neurotransmitter receptors, 410t
side effects of, 400t
Clonazepam
administration and uses of, 466t
metabolism of, 128t
pharmacokinetics of, 1826t
for pruritus, 1828t
side effects of, 138t
structure of, 459t
Clonidine
absorption, fate, and excretion of,
296
adrenergic receptors and, 206t
adverse effects and side effects of,
782
adverse effects of, 296
as antihypertensive agent, 774t,
781–782
arrhythmias caused by, 821t
hypoglycemia and, 1248t
for menopausal symptoms, 1840
pharmacokinetics of, 1826t
pharmacological properties of,
295–296
therapeutic uses of, 296–297, 782
Clonorchis sinensis, 1449
Clopidogrel
antiplatelet effects, site of action,
868f
for myocardial ischemia, 752
pharmacokinetics of, 1827t
polymorphisms and response to,
159t
structure of, 869f
Clorazepate
pharmacokinetics of, 1827t
structure of, 459t
Clostridial infections, penicillin for,
1487
Clostridium sordellii
septic shock, 1837
uterine infection, 1837
Clotrimazole, 1587, 1817
for vaginal candidiasis, 1842t
Cloxacillin, 1488
chemistry of, 1479t
properties of, 1479t
Clozapine, 350, 920
dosage of, 425t
metabolism of, 432t
pharmacokinetics of, 1827t
polymorphisms and response to,
160t
potencies at neurotransmitter
receptors, 427t
side effects of, 425t
CML. See Chronic myelogenous
leukemia (CML)
c-myc oncogene, 730
CNS. See Central nervous system
(CNS)
CNVs. See Copy number variations
(CNVs)
CoA. See Coenzyme A (CoA)
Coagulation, 849–853
major reactions of, 850f
nonenzymatic protein coafactors,
851–852
statins and, 895
vasopressin and, 708
Coagulation factor(s), functions of,
850f
Coating, enteric, 21
Cocaine
abuse and addiction, 661–663
as anesthetic, 572
cholinergic receptors and, 206t
metabolism of, 128t
Codeine
drug interactions with, 844
metabolism of, 128t
pharmacokinetics of, 1828t
polymorphisms and response to, 159t
Codominant trait, 147
Codons, 148f
Coenzyme A (CoA), 185
Cognition
dopamine and, 357
estrogen and, 1175
muscarinic receptors in, 223–224
Colchicine
absorption, 995
adverse effects and side effects of,
996
Colchicine (Cont.):
distribution of, 995
elimination, 995
mechanism of action of, 995
structure of, 995
therapeutic uses of, 995–996
Colesevelam, 898–899
adverse effects of, 899
chemistry of, 898–899
drug interactions with, 899
and lipoprotein levels, 899
and statins, combination therapy
with, 898
structure of, 898f
therapeutic uses of, 899
monitoring, 899
COLESTID (colestipol hydrochloride),
899
Colestipol, 898–899
adverse effects of, 899
chemistry of, 898–899
drug interactions with, 899
and lipoprotein levels, 899
and statins, combination therapy
with, 898
structure of, 898f
therapeutic uses of, 899
Colon cancer
drugs for, 1668t–1670t
metastatic, 1737
prevention of, NSAIDs for, 972–973
Colony-stimulating factor(s), in cancer
treatment, 1750
Colterol, structure of, 279t
Coma, myxedema, 1144–1145
COMBIGAN, 1787
Combination therapy, 50
Combinatorial chemistry, 4
Combined androgen blockade (CAB),
1765
COMBIPATCH (estradiol/norethindrone),
1839t
COMBUNOX, 988
Commodity, prescription as,
1882–1883
Common coagulation pathway, 853
Common cold, H 1
receptor antagonists
for, 922
Comncentration gradient, for
percutaneous drug
absorption, 1804
Compactin, 893
Competitive inhibition, 95
Compliance, prescription writing and,
1881–1882
2013
INDEX